High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer

Bone Marrow Transplantation

Volumn 18, Issue SUPPL. 1, 1996, Pages

  Zander, A R ^a   Kruger W ^a   Kroger N ^a   Damon, L ^a   Konigmann M ^a   Berdel, W E ^a   Gieseking, F ^a   Schafer Eckart K ^a   Mobus V ^a   Frickhofen, N ^a   Wandt, H ^a   Illiger, H J ^a   Metzner, B ^a   Kolbe, K ^a   Wormann B ^a   Trumper L ^a   Huber, C ^a   Hossfeld, D K ^a   Maass, H ^a   Jonat, W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; THIOTEPA;

ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MORTALITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 10244226702     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (8)

1. PETERS WP. High dose chemotherapy and autologous bone marrow support for breast cancer. In: De Vita VT, Hellmann S, Rosenberg SA (eds.): Important advances in oncology 1991; Philadelphia PA, Lippincott 1991; 135-140.
2. PETERS WP, ROSS M, VREDENBURG JJ, MEISENBERG B, MARKS LB, WINER E, KURTZBERG J, BAST RC JR, JONES R, SHPALL E, WU K, ROSNER G, GILBERT C, MATHIAS B, CONIGLIO D, PETROS W, HENDERSON IC, NORTON L, WEISS RB, BUDMANN D, HURD D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993, 11: 1132-1143.
3. PETERS WP, BERRY D, VREDENBURGH JJ, HUSSEIN A, RUBIN P, ELKORDY M, ROSS M, HENDERSON IC, BUDMANN D, NORTON L, WEISS R, HURD D. Five year follow up of high dose combination alkylating agents with abmt as consolidation after standard-dose CAF for primary breast cancer involving 10 axillary lymph nodes (Duke/CALGB 8782). Proc Am Soc Clin Oncol 1995; 14: 317 (meeting abstract).
4. ANTMANN K, AYASH L, ELIAS A, WHEELER C, HUNT M, EDE JP, TEICHER BA, CRITCHLOW J, BIBBO J, SCHNIPPER LE, FREI E. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
5. WILLIAMS SF, GILEWSKI T, MICK R, BITRAN J. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow up report. J Clin Oncol 1992; 10: 1743-1747.
6. LYDING J, DAMON L, WOLF J, LINKER C, RUGO H, COCKERILL K, ZANDER A. High-dose cyclophosphamide (C), thiotepa (T), and mitoxantrone (M) with autologous bone marrow transplantation (abmt) for breast cancer (BC). Proc Ann Am Soc Clin Oncol 1992: A105 (meeting abstract).
7. DAMON L, WOLF J, RUGO H, ZANDER A et. al: Cyclophosphamide, Thiothepa, and Mitoxantrone (CTM) with hematopoietic stem cell rescue for breast cancer (meeting abstract) 22. Deutscher Krebskongreß, Berlin, 1996.
8. BEARMAN SI, APPELBAUM FR, BUCKNER CD, PETERSEN FB, FISHER LD, CLIFT RA, THOMAS ED. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.